<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02721953</url>
  </required_header>
  <id_info>
    <org_study_id>29/14</org_study_id>
    <nct_id>NCT02721953</nct_id>
  </id_info>
  <brief_title>The Effects of Butyrate on Children With Obesity</brief_title>
  <official_title>Effects of Butyrate on Insulin Resistance in Children Affected by Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Butyrate is a short chain fatty acid (SCFA) produced by bacterial fermentation of undigested&#xD;
      starch in the gut. Butyrate carries out different effects at intestinal and extraintestinal&#xD;
      level, including: immune regulation with anti-inflammatory effect at intestinal and systemic&#xD;
      level and modulation of gut microbiota. Many of these effects result from an epigenetic&#xD;
      mechanism. Shown in an animal model of obesity induced by a high fat diet (HFD), that&#xD;
      butyrate can exercise very effective protective action against obesity through the&#xD;
      stimulation of intestinal satiety hormones. Shown always in murine model of obesity induced&#xD;
      by HFD, that butyrate is effective in preventing and treating obesity and insulin resistance.&#xD;
      After 5 weeks of treatment with butyrate was observed a reduction of 10.2% of body weight,&#xD;
      30% of fasting glucose and 50% insulin resistance.&#xD;
&#xD;
      In an animal model of metabolic syndrome with NAFLD researchers have recently demonstrated&#xD;
      that the administration of butyrate is able to significantly reduce insulin resistance, liver&#xD;
      damage, dyslipidaemia through a modulation of the inflammatory process.&#xD;
&#xD;
      Pharmacokinetic and pharmacodynamic studies in humans show that the oral administration of&#xD;
      butyrate is safe and well tolerated. The peak serum levels occurs 4-6 hours after oral&#xD;
      administration.&#xD;
&#xD;
      All of these data makes plausible a possible positive effect on insulin resistance in the&#xD;
      obese child.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of insulin resistance</measure>
    <time_frame>After 6 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of body weight</measure>
    <time_frame>After 6 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Insulin Resistance</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Hypocaloric diet plus butyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypocaloric diet plus butyrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypocaloric diet plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hypocaloric diet plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Butyrate</intervention_name>
    <description>Butyrate</description>
    <arm_group_label>Hypocaloric diet plus butyrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Hypocaloric diet plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obesity (BMI &gt;95° percentile)&#xD;
&#xD;
          -  HOmeostasis Model Assessment (HOMA-IR) &gt; 4 (obtained by calculating the product of&#xD;
             fasting plasma insulin expressed in microunits/mL and fasting plasma glucose expressed&#xD;
             in mmol/L divided by 22.5)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;10 or &gt;15 years&#xD;
&#xD;
          -  BMI &lt;95° centile&#xD;
&#xD;
          -  HOMA-IR &lt;4&#xD;
&#xD;
          -  Patients under pharmacological treatment for obesity (metformin) or taking vitamin E,&#xD;
             pre-, pro- or synbiotics&#xD;
&#xD;
          -  Simultaneous presence of other chronic diseases unrelated to obesity (cancer,&#xD;
             immunodeficiency, cystic fibrosis, allergies, celiac disease, autoimmune diseases,&#xD;
             neuropsychiatric disorders, type 1 diabetes, inflammatory bowel diseases,&#xD;
             malformations of urinary or gastrointestinal or respiratory tract, chronic lung&#xD;
             diseases, genetic and metabolic diseases, chronic hematological diseases)&#xD;
&#xD;
          -  History of surgery for the treatment of obesity&#xD;
&#xD;
          -  Any medical condition that may interfere with participation in this study&#xD;
&#xD;
          -  Participation in other clinical trials still in progress&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Naples Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Berni Canani, MD, PhD</last_name>
      <phone>+390817462680</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2016</study_first_posted>
  <last_update_submitted>March 29, 2016</last_update_submitted>
  <last_update_submitted_qc>March 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Roberto Berni Canani</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

